Antiplatelet therapies for the treatment of cardiovascular disease (Q37684794)

22 August 2017

1 reference

title

Antiplatelet therapies for the treatment of cardiovascular disease (English)

1 reference

22 August 2017

cardiovascular disease

1 reference

Alan D Michelson

1

1 reference

22 August 2017

1 February 2010

1 reference

Nature Reviews Drug Discovery

22 August 2017

1 reference

22 August 2017

9

1 reference

22 August 2017

2

1 reference

22 August 2017

154-169

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2957

22 August 2017

0 references

cites work

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization

31 March 2020

1 reference

Platelet antistaphylococcal responses occur through P2X1 and P2Y12 receptor-induced activation and kinocidin release.

31 March 2020

1 reference

Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released

31 March 2020

1 reference

The Evolution of Mammalian Platelets

31 March 2020

1 reference

Acetylation of prostaglandin synthase by aspirin

31 March 2020

1 reference

The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase

31 March 2020

1 reference

Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

31 March 2020

1 reference

Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis

31 March 2020

1 reference

Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis

31 March 2020

1 reference

Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests

31 March 2020

1 reference

P2Y12 antagonism: promises and challenges

31 March 2020

1 reference

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

31 March 2020

1 reference

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

31 March 2020

1 reference

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

31 March 2020

1 reference

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

31 March 2020

1 reference

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

31 March 2020

1 reference

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

31 March 2020

1 reference

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

31 March 2020

1 reference

An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial

31 March 2020

1 reference

Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.

31 March 2020

1 reference

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

31 March 2020

1 reference

Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study

31 March 2020

1 reference

High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome

31 March 2020

1 reference

Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.

31 March 2020

1 reference

Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?

31 March 2020

1 reference

Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis

31 March 2020

1 reference

Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis

31 March 2020

1 reference

Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up

31 March 2020

1 reference

Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events.

31 March 2020

1 reference

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study

31 March 2020

1 reference

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

31 March 2020

1 reference

Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation.

31 March 2020

1 reference

Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study

31 March 2020

1 reference

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

31 March 2020

1 reference

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome

31 March 2020

1 reference

Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel

31 March 2020

1 reference

Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.

31 March 2020

1 reference

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

31 March 2020

1 reference

The association of cigarette smoking with enhanced platelet inhibition by clopidogrel

31 March 2020

1 reference

Interaction between cigarette smoking and clinical benefit of clopidogrel

31 March 2020

1 reference

Cytochrome p-450 polymorphisms and response to clopidogrel

31 March 2020

1 reference

Genetic determinants of response to clopidogrel and cardiovascular events

31 March 2020

1 reference

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

31 March 2020

1 reference

Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'

31 March 2020

1 reference

Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.

31 March 2020

1 reference

High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.

31 March 2020

1 reference

The difference between clopidogrel responsiveness and posttreatment platelet reactivity

31 March 2020

1 reference

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

31 March 2020

1 reference

Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment

31 March 2020

1 reference

Thrombosis and drug-eluting stents: an objective appraisal

31 March 2020

1 reference

Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile

31 March 2020

1 reference

The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite

31 March 2020

1 reference

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation

31 March 2020

1 reference

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

31 March 2020

1 reference

Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel

31 March 2020

1 reference

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

31 March 2020

1 reference

Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial

31 March 2020

1 reference

Prasugrel versus clopidogrel in patients with acute coronary syndromes

31 March 2020

1 reference

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

31 March 2020

1 reference

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

31 March 2020

1 reference

Preclinical and clinical studies with selective reversible direct P2Y12 antagonists

31 March 2020

1 reference

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

31 March 2020

1 reference

Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE

31 March 2020

1 reference

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes

31 March 2020

1 reference

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

31 March 2020

1 reference

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial

31 March 2020

1 reference

αIIbβ3 (GPIIb-IIIa) Antagonists

31 March 2020

1 reference

An Abnormal Platelet Glycoprotein Pattern in Three Cases of Glanzmann's Thrombasthenia

31 March 2020

1 reference

Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics

31 March 2020

1 reference

In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time

31 March 2020

1 reference

Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

31 March 2020

1 reference

Networking in the hemostatic system. Integrin alphaiibbeta3 binds prothrombin and influences its activation

31 March 2020

1 reference

Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?

31 March 2020

1 reference

Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials

31 March 2020

1 reference

Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa).

31 March 2020

1 reference

Application of high-throughput screening to identify a novel alphaIIb-specific small- molecule inhibitor of alphaIIbbeta3-mediated platelet interaction with fibrinogen.

31 March 2020

1 reference

Antiaggregatory and proangiogenic effects of a novel recombinant human dual specificity anti-integrin antibody

31 March 2020

1 reference

Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation

31 March 2020

1 reference

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

31 March 2020

1 reference

Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial

31 March 2020

1 reference

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

31 March 2020

1 reference

Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention

31 March 2020

1 reference

Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial)

31 March 2020

1 reference

A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.

31 March 2020

1 reference

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study

31 March 2020

1 reference

A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex

31 March 2020

1 reference

Small-molecule inhibitors of integrin alpha2beta1 that prevent pathological thrombus formation via an allosteric mechanism

31 March 2020

1 reference

In Vivo Antithrombotic Effects of a Nitric Oxide-Releasing Aspirin Derivative, NCX-4016

31 March 2020

1 reference

Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG

31 March 2020

1 reference

The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons.

31 March 2020

1 reference

Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin

31 March 2020

1 reference

Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model

31 March 2020

1 reference

Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis

31 March 2020

1 reference

Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation

31 March 2020

1 reference

Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism

31 March 2020

1 reference

Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist

31 March 2020

1 reference

Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin

31 March 2020

1 reference

The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies.

31 March 2020

1 reference

Distinct effects of z-335, a new thromboxane A2 receptor antagonist, on rabbit platelets and aortic smooth muscle

31 March 2020

1 reference

The Thromboxane Receptor Antagonist PBT-3, a Hepoxilin Stable Analog, Selectively Antagonizes the TPα Isoform in Transfected COS-7 Cells

31 March 2020

1 reference

Effects of selective cyclooxygenase inhibitors on ischemia/reperfusion-induced hepatic microcirculatory dysfunction in mice

31 March 2020

1 reference

Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane

31 March 2020

1 reference

Thromboxane A2 receptor density increases during chronic exposure to thromboxane A2 receptor antagonists after porcine carotid bypass

31 March 2020

1 reference

Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study

31 March 2020

1 reference

Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function

31 March 2020

1 reference

Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion

31 March 2020

1 reference

Antiaggregating and vasodilatory effects of a new nitroderivative of acetylsalicylic acid

31 March 2020

1 reference

Antagonists of the EP3 receptor for prostaglandin E2 are novel antiplatelet agents that do not prolong bleeding

31 March 2020

1 reference

Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin alpha(IIb)beta(3).

31 March 2020

1 reference

Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat.

31 March 2020

1 reference

Discovery-based strategies for studying platelet function

31 March 2020

1 reference

Platelet membrane proteomics: a novel repository for functional research

31 March 2020

1 reference

Methods for the measurement of platelet function

31 March 2020

1 reference

Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists

31 March 2020

1 reference

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

31 March 2020

1 reference

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

31 March 2020

1 reference

Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis

31 March 2020

1 reference

Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.

31 March 2020

1 reference

Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patien

31 March 2020

1 reference

The Glycoprotein Ib-IX-V Complex

31 March 2020

1 reference

P-Selectin/PSGL-1 and Other Interactions between Platelets, Leukocytes, and Endothelium

31 March 2020

1 reference

Coagulation 2006: a modern view of hemostasis.

31 March 2020

1 reference

Mechanisms of thrombus formation

31 March 2020

1 reference

A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease

31 March 2020

1 reference

GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood

31 March 2020

1 reference

12 December 2020

Cardioprotective actions of the specific thromboxane receptor antagonist (+)-S145Na following coronary occlusion and reperfusion in the rat.

1 reference

12 December 2020

Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes

1 reference

12 December 2020

A snake venom metalloproteinase, kistomin, cleaves platelet glycoprotein VI and impairs platelet functions

1 reference

12 December 2020

Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis.

1 reference

12 December 2020

Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review

1 reference

12 December 2020

Platelets and wound healing

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD2957

1 reference

22 August 2017

1 reference

PubMed ID

20118963